New psychoactive substances (NPS) are a heterogeneous group of substances. They are
associated with a number of health and social harms on an individual and societal level …

Adherence to antipsychotics improves outcome in schizophrenia. There is a lack of
consensus on which factors most influence adherence behaviour and methodological …

Depression is a potentially life-threatening disorder affecting millions of people across the
globe. It is a huge burden to both the individual and society, costing over£ 9 billion in 2000 …

The burden of depressive disorders and the frequent inadequacy of their current
pharmacological treatments are well established. The anaesthetic and hallucinogenic drug …

Bupropion has been used as an antidepressant for over 20 years, though its licence for such
use varies and it is typically a third-or fourth-line agent. It has a unique pharmacology …

There is an urgent need to provide evidence-based well-being and mental health support for
front-line clinical staff managing the COVID-19 pandemic who are at risk of moral injury and …

Hallucinogens have been part of spiritual practice for millennia, but controversy surrounding
their mind-manifesting effects led to their proscription by the mid-20th century, largely …

Lithium has been used for the treatment of mood disorders for over 60 years, yet the exact
mechanisms by which it exerts its therapeutic effects remain unclear. Two enzymatic chains …

There has been growing clinical, public, and media awareness and concern about the
availability and potential harmfulness of so-called 'legal highs', which are more appropriately …

In 2016 the Psychoactive Substances Bill banned trading but not possession of all current
and future novel psychoactive substances (NPS), sometimes incorrectly called “legal highs,” …